Organisation paid for research Program year 2025 Source: CMS Open Payments

Access Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,016,648

286 payments

Through program year 2025, Access Clinical Trials is reported as receiving $1,016,648 in research payments, across 286 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$3,314	4
2021	Research	$276,121	137
2020	Research	$399,361	89
2019	Research	$337,852	56

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $1,016,648 286 payments

Studies the money was for Research payments · program years 2019–2025

M14-702 $519,419 125 payments
M16-824 $205,919 18 payments
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain $142,834 75 payments
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain $117,818 54 payments
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $15,469 8 payments
M18-969 $11,875 2 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) $1,440 1 payment
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age $674 1 payment
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine $600 1 payment
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age. $600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.